Pain Control After Orthognathic Surgery (PCOGS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will assess the efficacy and safety of levobupivacaine for postoperative pain control in patients received orthognathic surgery. In this split-mouth study, each side will be randomized to receive 1) 5ml 0.5% levobupivacine, 2) 2.5ml 0.5% levobupivacaine, or 3) placebo. One shot of these agents will be delivered by nerve block to maxillary and mandibular branches of trigeminal nerve before the incision was made. The degree of postoperative pain will be evaluated daily by visual analog scale for up to 3 days. The anticipated time on study is 1 year, and the target sample size is 40 individuals.
| Condition | Intervention |
|---|---|
|
Postoperative Pain |
Procedure: Trigeminal nerve block |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Intra-operative Trigeminal Nerve Block For Post-operative Pain Control After Orthognathic Surgery |
- Postoperative pain [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3days ] [ Designated as safety issue: No ]The degree of pain will be measured daily by visual analog scale.
- Effective duration of levobupivacaine nerve block [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 5ml 5% levobupivacaine
5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
|
Procedure: Trigeminal nerve block
5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
Other Name: 5ml Chirocaine
|
|
Placebo Comparator: 5ml normal saline
5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
|
Procedure: Trigeminal nerve block
5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
Other Name: Placebo
|
|
Experimental: 2.5ml 5% levobupivacaine
2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
|
Procedure: Trigeminal nerve block
2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
Other Name: 2.5ml Chirocaine
|
Detailed Description:
Design of intervention vs. control Intra-operative injective of (chirocaine) before incision Location of injection: inferior alveolar nerve proximal to its entrance to ramus of mandible, maxillary nerve around pterygopalatine ganglion Amount of injection on each injection site: (1) Experimental group 1: 5mg/ml chirocaine 5cc (2)Experimental group 2: 5mg/ml chirocaine 2.5cc (3)Control group: normal saline 5cc. There are totally 4 injection sites for two jaw surgery and 2 injection sites for one jaw surgery. The experimental site and control site will be determined randomly before injection.
Outcome measurement
- Primary: effectiveness of intra-operative nerve block on post-operative pain control
Secondary:
- whether the pain relieve effect is dose-related
- how long will this effect last
The intensity of post-operative pain will be measured by VAS, visual analog scale)daily until patients are discharged.
Report adverse outcome:
- Intolerable pain on control group
- Adverse reaction to local anesthetic agent
- Injection-related complications (puncture of major vessels, hematoma on -injection site, etc.)
Eligibility| Ages Eligible for Study: | 20 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- all patients who will receive orthognathic surgery (one jaw or two jaw, with or without genioplasty) in Chang Gung Memorial Hospital since July 2011
Exclusion Criteria:
- more complex (2- or more piece LeFort I osteotomy, combined gonial resection in BSSO, etc.) or less complex (only Wassmund and/or Kole osteotomies in upper or lower jaw) orthognathic procedures
- unexpected fracture (unilateral)
- intra-operative nerve injuries
- significant facial asymmetry which demands different procedures (location of osteotomy, extension of muscle stripping, etc.)
- cleft patient, post-traumatic patients, patients with craniofacial syndromes or other neurological or systemic problems which might interfere pain evaluation post-operatively
Contacts and Locations| Contact: Yi-Chieh Chen, MD | +886-975-365553 | Pschenyc@yahoo.com.tw |
| Taiwan | |
| Chang Gung Memorial Hospital | Recruiting |
| Taipei, Taiwan, 10507 | |
| Contact: Yi-Chieh Chen, MD Pschenyc@yahoo.com.tw | |
| Principal Investigator: Yi-Chieh Chen, MD | |
| Principal Investigator: | Yi-Chieh Chen, MD | Chang Gung Memorial Hospital |
More Information
No publications provided
| Responsible Party: | Chang Gung Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT01418183 History of Changes |
| Other Study ID Numbers: | 100-0548A3 |
| Study First Received: | August 12, 2011 |
| Last Updated: | September 4, 2011 |
| Health Authority: | Taiwan: Institutional Review Board |
Keywords provided by Chang Gung Memorial Hospital:
|
Orthognathic surgery Pain control Trigeminal nerve Levobupivacaine |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Levobupivacaine Bupivacaine Anesthetics, Local |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013